HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?

[1]  Jean-Michel Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.

[2]  M. Milella,et al.  The elderly and direct antiviral agents: Constraint or challenge? , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[3]  M. Massari,et al.  Safety and efficacy of direct‐acting antivirals for the treatment of chronic hepatitis C in a real‐world population aged 65 years and older , 2017, Journal of viral hepatitis.

[4]  A. Schoepfer,et al.  Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[5]  S. Antinori,et al.  Direct‐acting antivirals in hepatitis C virus (HCV)‐infected and HCV/HIV‐coinfected patients: real‐life safety and efficacy , 2017, HIV medicine.

[6]  M. Buti,et al.  Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real‐life cohort , 2017, Journal of viral hepatitis.

[7]  M. Milella,et al.  Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study. , 2017, International journal of antimicrobial agents.

[8]  R. Flisiak,et al.  Hepatitis C: efficacy and safety in real life , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[9]  R. Bruno,et al.  Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients With HIV/HCV Coinfection: Results of an Italian Compassionate Use Program , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  J. Rockstroh,et al.  Daclatasvir plus Sofosbuvir, with or without Ribavirin, in Real-World Patients with HIV–HCV Coinfection and Advanced Liver Disease , 2016, Antiviral therapy.

[11]  J. Pawlotsky,et al.  Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[12]  M. Manns,et al.  Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  M. Stepanova,et al.  Sofosbuvir and ledipasvir improve patient‐reported outcomes in patients co‐infected with hepatitis C and human immunodeficiency virus , 2016, Journal of viral hepatitis.

[14]  L. Bolondi,et al.  Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. , 2016, Journal of hepatology.

[15]  T. Hassanein,et al.  High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. , 2016, Gastroenterology.

[16]  G. Cabibbo,et al.  Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing. , 2016, Journal of hepatology.

[17]  J. Bruix,et al.  Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. , 2016, Journal of hepatology.

[18]  M. Colombo,et al.  Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. , 2016, Journal of hepatology.

[19]  C. Berg,et al.  Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12 , 2016, World journal of gastroenterology.

[20]  D. Neau,et al.  All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  F. Ceccherini‐Silberstein,et al.  From current status to optimization of HCV treatment: Recommendations from an expert panel. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[22]  F. Palella,et al.  High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective. , 2016, The Journal of antimicrobial chemotherapy.

[23]  S. Zeuzem,et al.  The efficacy and safety of direct acting antiviral treatment and clinical significance of drug–drug interactions in elderly patients with chronic hepatitis C virus infection , 2016, Alimentary pharmacology & therapeutics.

[24]  D. Dieterich,et al.  Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  A. Branch,et al.  Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  S. Pol.  Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. , 2016, Journal of hepatology.

[27]  E. Yoshida,et al.  Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2) , 2016, Hepatology.

[28]  M. Sulkowski.  HCV‐HIV co‐infected patients: no longer a ‘special’ population? , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[29]  T. Berg,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. , 2015, The New England journal of medicine.

[30]  G. Dore,et al.  Epidemiology and natural history of HCV infection , 2013, Nature Reviews Gastroenterology &Hepatology.

[31]  Laurent Castera,et al.  Non-invasive evaluation of liver fibrosis using transient elastography. , 2008, Journal of hepatology.

[32]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[33]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.